Sygnature Discovery
Dr. Bodo Spöri told us he looks forward to further raising global awareness of Sygnature Discovery in his new role as the company’s senior director of business development, DMPK services.
“In particular in the DMPK area, the strength of the team already in place and the recent hires demonstrate Sygnature’s commitment to thought leadership and ‘support beyond data’ for our clients, adding value for both stand-alone and integrated ADME-Tox projects in discovery and regulatory settings,” he said.
Spöri has worked at Cyprotex and Domainex, as well as in academia.